Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study

EK Bancroft; EC Page; E Castro; H Lilja; A Vickers; D Sjoberg; M Assel; CS Foster; G Mitchell; K Drew; L Mæhle; K Axcrona; DG Evans; B Bulman; D Eccles; D McBride; C Van Asperen; H Vasen; LA Kiemeney; J Ringelberg; C Cybulski; D Wokolorczyk; C Selkirk; PJ Hulick; A Bojesen; AB Skytte; J Lam; L Taylor; R Oldenburg; R Cremers; G Verhaegh; WA Van Zelst-Stams; JC Oosterwijk; I Blanco; M Salinas; J Cook; DJ Rosario; S Buys; T Conner; MG Ausems; KR Ong; J Hoffman; S Domchek; J Powers; MR Teixeira; S Maia; WD Foulkes; N Taherian; M Ruijs; ATHV Den Enden; L Izatt; R Davidson; MA Adank; L Walker; R Schmutzler; K Tucker; J Kirk; S Hodgson; M Harris; F Douglas; GJ Lindeman; J Zgajnar; M Tischkowitz; VE Clowes; R Susman; T Ramón Y Cajal; N Patcher; N Gadea; A Spigelman; T Van Os; A Liljegren; L Side; C Brewer; AF Brady; A Donaldson; V Stefansdottir; E Friedman; R Chen-Shtoyerman; DJ Amor; L Copakova; J Barwell; VN Giri; V Murthy; N Nicolai; SH Teo; L Greenhalgh; S Strom; A Henderson; J McGrath; D Gallagher; N Aaronson; A Ardern-Jones; C Bangma; D Dearnaley; P Costello; J Eyfjord; J Rothwell; A Falconer; H Gronberg; FC Hamdy

Journal article

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study

EK Bancroft, EC Page, E Castro, H Lilja, A Vickers, D Sjoberg, M Assel, CS Foster, G Mitchell, K Drew, L Mæhle, K Axcrona, DG Evans, B Bulman, D Eccles, D McBride, C Van Asperen, H Vasen, LA Kiemeney, J Ringelberg Show all

European Urology | Published : 2014

DOI: 10.1016/j.eururo.2014.01.003

Abstract

Background Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an international consortium of 62 centres in 20 countries evaluating the use of targeted PCa screening in men with BRCA1/2 mutations. Objective To report the first year's screening results for all men at enrolment in the study. Design, setting and participants We recruited men aged 40-69 yr with germline BRCA1/2 mutations and a control group of men who have t..

View full abstract

University of Melbourne Researchers

Geoffrey Lindeman Author

David Amor Author

Lara Petelin Author

Sibel Saya Author

Related Projects (1)

THE KATHLEEN CUNNINGHAM FOUNDATION CONSORTIUM FOR RESEARCH INTO FAMILIAL BREAST CANCER

Grants

Awarded by National Cancer Institute

Funding Acknowledgements

Rosalind A. Eeles certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Hans Lilja holds patents for free PSA, hK2, and intact PSA assays. Rosalind A. Eeles has received educational grants from Janssen Pharmaceuticals, GenProbe (formerly Tepnel), Illumina, and Vista Diagnostics and honoraria from Succinct Communications.